August 2026– date –
-
ARPA-H Launches AEGIS Project: Affordable Gene-Editing Therapies for Pediatric Immune Diseases via CRISPR and LNP Delivery
Princeton University USA Overview The ARPA-H THRIVE-funded AEGIS project is pioneering the development of affordable gene-editing therapies for children suffering from rare inborn errors of immunity (IEIs). By leveraging advanced CRISPR ... -
Hopstem’s iPSC-Derived Neural Progenitor Cell hNPC01 Receives FDA IND Clearance and Fast Track Designation for Stroke and Traumatic Brain Injury
AllSci USA Overview Hopstem Biotechnology announced that its allogeneic iPSC-derived forebrain neural progenitor cell therapy, hNPC01, received both IND clearance and Fast Track designation from the U.S. FDA for treating chronic motor de... -
AI Unlocks CAR T Durability: Single-Cell Models Predict Lasting Remission, Identify Novel Biomarker in B-ALL
bioRxiv USA Overview While CD19-targeted CAR T-cell therapy offers significant hope for B-cell Acute Lymphoblastic Leukemia (B-ALL) patients, approximately half experience relapse within a year. A new study demonstrates that single-cell ... -
FDA Flexibilizes Cell and Gene Therapy CMC Regulations, Eliminating ‘Rule of Three’ to Accelerate Development
BioProcess International USA Overview The U.S. FDA has announced a flexible Chemistry, Manufacturing, and Controls (CMC) guidance for Cell and Gene Therapy (CGT) products, effectively ending the traditional 'Rule of Three' validation req... -
4D Printing and Smart Hydrogels Revolutionize Regenerative Wound Therapy: Vascularized Scaffolds Enable Precision Drug Delivery
Polymers (PMC) Global Overview New paradigms are emerging in precision drug delivery and regenerative wound therapy, spanning from smart hydrogel design to 4D-printed scaffolds. Advances in 3D bioprinting now enable the fabrication of va... -
Ultra-Homotypic Targeting: Lanthanide-Modified EVs Boost Cancer Detection Sensitivity by Over 25-Fold
University of Tokyo Japan Overview Researchers at the University of Tokyo, led by Professor Keisuke Goda, have unveiled a groundbreaking 'ultra-homotypic targeting' technology. By engineering extracellular vesicles (EVs) with lanthanide ... -
Children’s Hospital of Philadelphia Develops CAR T-Cell Therapy for Pediatric Solid Tumors: First Human Trial Targets PHOX2B-Derived Peptides
Children's Hospital of Philadelphia (CHOP) USA Overview Researchers at Children's Hospital of Philadelphia (CHOP) are leading the development of CAR T-cell therapies for pediatric solid tumors like neuroblastoma. A 'peptide-centric' (PC-... -
Advanced CAR-T/NK Therapies for Solid Tumors: iPSC-Derived CAR-NK Cells Show Promise in Efficacy and Safety
Oncodaily Global Overview In solid tumor treatment, IL-15 armed GPC3 CAR-T cells demonstrated promising early data, with cytokine release syndrome (CRS) managed by an inducible caspase-9 switch. Notably, iPSC-derived IL-15 incorporated C... -
Future of CAR T-Cell Therapy: Multi-Target, Off-the-Shelf Strategies and Manufacturing Innovation to Overcome Solid Tumors
Frontiers in Molecular Medicine Global Overview While CAR T-cell therapy revolutionized hematologic cancer treatment, challenges persist in solid tumors, including antigen heterogeneity, immunosuppressive tumor microenvironments, and poo... -
Converging 3D Bioprinting and Organoids: A Novel Approach Revolutionizing Disease Modeling and Regenerative Medicine
Oxford Academic (Regenerative Biomaterials) Global Overview The convergence of 3D bioprinting and organoid technology presents a new paradigm poised to revolutionize disease modeling, drug screening, and regenerative medicine. 3D bioprin...
